相关实验视频

Updated: Jun 10, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

从显微镜到分子:前列腺癌诊断的演变

Junyue Tao¹, Xiaokang Bian¹, Jun Zhou¹

¹Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

|October 11, 2024

概括

分子诊断正在通过识别TMPRSS2-ERG融合和PTEN突变等关键遗传标记来彻底改变前列腺癌 (PCa) 检测. 这种精确的方法提高了早期诊断和个性化治疗策略,以获得更好的患者结果.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
分子诊断学分子诊断学

背景情况:

前列腺癌 (PCa) 仍然是男性的主要全球恶性瘤.
传统的细胞病理学在充分描述PCa的复杂性方面面临限制.
早期,精确的诊断方法的需要对于有效的管理至关重要.

研究的目的:

审查前列腺癌分子诊断方面的进展.
探索分子生物标志物在PCa病理和治疗中的作用.
突出分子诊断和细胞病理学之间的协同作用.

主要方法:

关于PCa分子诊断和生物标志物的综合文献综述.
对遗传异常的分析,包括TMPRSS2-ERG融合,PTEN和MYC突变.
对分子标记物的检测技术的评估.

主要成果:

分子诊断为PCa的发病,进展和治疗抵抗提供了洞察力.
确定了关键的遗传因素:TMPRSS2-ERG融合,PTEN和MYC突变.
将分子诊断与细胞病理学结合在一起的多模式方法显示出有希望.

结论:

分子诊断与细胞病理学的整合对于有效的PCa管理至关重要.
基于基因构成的个性化治疗策略可以改善预后.
未来的PCa护理涉及量身定制的疗法和对疾病轨迹的预测性见解.

关键词:

生物标志物生物标志物一代的序列化代的序列化液体活检液体活检分子诊断是一种分子诊断.前列腺癌是什么意思前列腺癌是什么意思

更多相关视频

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...